Optimizing Anticoagulation in Valvular Heart Disease: Navigating NOACs and VKAs
Authors:
- Anca OuatuAnca Ouatu
- Oana Nicoleta Buliga-FinișOBOana Nicoleta Buliga-Finiș
- Daniela Maria TanaseDaniela Maria Tanase
- Minerva Codruta BadescuMinerva Codruta Badescu
- Nicoleta DimaNicoleta Dima
- Mariana FloriaMFMariana Floria
- Diana PopescuDPDiana Popescu
- Patricia RichterPRPatricia Richter
- Ciprian RezusCiprian Rezus
Open Access
- 20 September 2024
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 1002
Abstract
Background/Objectives: Non-vitamin K antagonist oral anticoagulants (NOACs) have demonstrated similar effectiveness and safety profiles to vitamin K antagonists (VKAs) in treating nonvalvular atrial fibrillation (AF). Given their favorable pharmacological profile, including the rapid onset and offset of action, fixed dosing, and predictable pharmacokinetics with a consistent dose-response relationship, reducing the need for frequent blood tests, researchers have investigated the potential of NOACs in patients with AF and valvular heart disease (VHD). Methods: Clinical trials, excluding patients with mechanical prosthetic valves or moderate/severe mitral stenosis, have shown the benefits of NOACs over VKAs in this population. However, there is a need for further research to determine if these findings apply to mechanical valve prostheses and NOACs. Results: Several ongoing randomized controlled trials are underway to provide more definitive evidence regarding NOAC treatment in moderate to severe rheumatic mitral stenosis. Importantly, recent trials that included patients with atrial fibrillation and bioprosthetic valves (also transcatheter heart valves) have provided evidence supporting the safety of NOACs in this specific patient population. Ongoing research aims to clearly define the specific scenarios where NOACs can be safely and effectively prescribed for various types of VHD, including moderate/severe mitral stenosis and mechanical valves. Conclusions: The aim of this review is to accurately identify the specific situations in which NOACs can be prescribed in patients with VHD, with a focus centered on each type of valvulopathy.Keywords
This publication has 88 references indexed in Scilit:
- Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized TrialThe Annals of Thoracic Surgery, 2023
- RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trialInternational Journal of Cardiology, 2022
- Oral anticoagulant use in patients with atrial fibrillation and mitral valve repairAmerican Heart Journal, 2021
- The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationAmerican Heart Journal, 2020
- Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trialClinical Cardiology, 2019
- Antithrombotic Therapy for Atrial FibrillationChest, 2018
- Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical ProsthesisThe American Journal of Cardiology, 2018
- NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantationClinical Research in Cardiology, 2018
- Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort studyHeart Rhythm, 2016
- Stroke prevention in atrial fibrillation—An Asian stroke perspectiveHeart Rhythm, 2013